



*Press release*

*Stockholm, Sept 3, 2010*

## Interim Report – January to June 2010

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the First Half of 2010.

### Financial Highlights

- Revenue for the first six months of 2010 was SEK 11.7 (12.7) million
- Net loss for the period amounted to SEK -14.1 (-11.4) million
- Earnings per share was SEK -0.19 (-0.38)
- Cash flow from current operations was SEK -13.3 (-27.1) million
- SEK 27.6m raised in additional financing of which 23.8m in cash

### Key Corporate Highlights

- During the period Affibody signed an agreement with an undisclosed company regarding its HER2 molecular imaging program, which includes ABY-025.
- The Swedish Governmental Agency for Innovation Systems (VINNOVA) has awarded Affibody a grant from their Innovations for Future Health program. The grant will enable Affibody to take the Albumod™ technology to human clinical testing.
- The Swedish MPA (Läkemedelsverket) has approved an exploratory clinical study in breast cancer patients at Uppsala University Hospital, Uppsala, Sweden with Affibody’s lead molecular imaging agent, ABY-025.
- The share issue directed to existing shareholders raised SEK 27.6 million gross to the company after which the total number of shares increased to 102 858 403.

David Bejker CEO, said: *“It is encouraging to observe that the strategy that was implemented in late 2008 has started to pay off. We are now well on track to become a cash flow positive company. Affibody has also ensured that clinical data will be available for both our platforms in a very cash efficient way”.*

### Enquiries

David Bejker, CEO  
Johan Stuart CFO

+46 706 454 948

+46 706 644 096

## About Affibody

Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody® molecules, which are small, robust and easily produced, can be designed to bind specifically to a large number of target proteins. They have a broad range of applications including protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostics, including molecular imaging, and targeted therapeutics.

Affibody is also commercializing its unique albumin binding technology Albumod™, together with own Affibody®- molecules or with other biotherapeutics. The technology is designed to enhance the efficacy of biotherapeutics by extending their circulation time.

Affibody has already developed biotechnological products that are commercialized by GE, Agilent and Finnzymes, and is developing molecules for therapeutic application in collaboration with Biovitrum.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: [www.affibody.com](http://www.affibody.com)



Lindhagensgatan 133, SE-112 51 Stockholm, Sweden.  
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, [www.affibody.com](http://www.affibody.com)